Institute of Biochemistry and Molecular Biology, University of Hamburg, Hamburg, Germany.
Clin Exp Allergy. 2012 Jun;42(6):976-85. doi: 10.1111/j.1365-2222.2012.03966.x.
As hymenoptera venoms are one of the allergen sources causing the highest incidence of anaphylaxis and sometimes fatal consequences, the detailed characterization of all venom allergens is imperative for design of component-resolved diagnostic approaches and improved intervention strategies.
Our aim was the immunochemical characterization of major royal jelly proteins (MRJP) 8 and 9, both components identified in honeybee venom (HBV) and putative allergens.
Both MRJPs were recombinantly produced as soluble differentially glycosylated proteins providing a defined degree of reactivity to cross-reactive carbohydrate determinants (CCD) in insect cells. Allergen-specific IgE(sIgE) reactivity of HBV-allergic patients was analysed by ELISA and immunoblotting.
MRJP8 and MRJP9 were identified as venom components by MS-based proteomic analyses. In a population of 47 HBV-allergic patients, reactivities with CCD-carrying MRJPs were in the range of 56% (61%), underlining the contribution of CCDs to allergen-binding. Beyond CCD-reactivity, 15% of patients showed sIgE reactivity with MRJP8 and 34% with MRJP9 respectively. These reactivities roughly in the range of Api m 2 render the MRJPs minor, but important allergens.
The glycosylated MRJP8 and MRJP9 of HBV have IgE-sensitizing potential in HBV-allergic patients beyond CCD reactivity and have to be considered as allergens, which might be potentially important for a fraction of venom allergic patients. They are valuable tools to elucidate individual component-resolved reactivity profiles of venom allergic patients and to provide insights into the role of particular venom components. Due to their allergenic properties, MRJP8 and MRJP9 were designated as isoallergens Api m 11.0101 and Api m 11.0201 respectively.
由于膜翅目毒液是引起过敏反应发生率最高、有时甚至致命后果的过敏原来源之一,因此详细描述所有毒液过敏原对于设计基于成分的诊断方法和改进干预策略至关重要。
我们的目的是对蜂王浆蛋白(MRJP)8 和 9 进行免疫化学表征,这两种蛋白均为蜜蜂毒液(HBV)中的成分,也是潜在的过敏原。
这两种 MRJP 均以可溶的、差异糖基化的蛋白形式进行重组表达,从而在昆虫细胞中提供对交叉反应性碳水化合物决定簇(CCD)的一定程度的反应性。通过 ELISA 和免疫印迹分析 HBV 过敏患者的过敏原特异性 IgE(sIgE)反应性。
MRJP8 和 MRJP9 通过基于 MS 的蛋白质组学分析被鉴定为毒液成分。在 47 名 HBV 过敏患者的人群中,对携带 CCD 的 MRJP 的反应性在 56%(61%)之间,这强调了 CCD 对过敏原结合的贡献。除 CCD 反应性外,15%的患者对 MRJP8 具有 sIgE 反应性,34%的患者对 MRJP9 具有 sIgE 反应性。这些反应性大致在 Api m 2 的范围内,使得 MRJPs 成为次要但重要的过敏原。
HBV 的糖基化 MRJP8 和 MRJP9 在 HBV 过敏患者中具有 IgE 致敏潜力,超出了 CCD 反应性,并且被认为是过敏原,这可能对一部分毒液过敏患者很重要。它们是阐明毒液过敏患者个体成分分辨反应谱并深入了解特定毒液成分作用的有价值工具。由于其过敏原特性,MRJP8 和 MRJP9 分别被指定为 Api m 11.0101 和 Api m 11.0201 等过敏原。